Status:
COMPLETED
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Lead Sponsor:
Pfizer
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE2
Brief Summary
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Detailed Description
Primary study objectives include are to determine the pharmacodynamic (PD) profiles for treatment doses of dalteparin in pediatric subjects of different ages with cancer and venous thromboembolism (VT...
Eligibility Criteria
Inclusion
- \-
Exclusion
- \-
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00952380
Start Date
August 1 2009
End Date
March 1 2018
Last Update
April 16 2019
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
2
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States, 20007
3
Nemours Children's Clinic
Jacksonville, Florida, United States, 32207
4
Wolfson Children's Hospital
Jacksonville, Florida, United States, 32207